Compare Stocks: ZURA, NVAX, NTLA, and ABSI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$9.74 -9.1%	$8.71	$2.24 ▼ $12.06	$1.84B	2.42	3.58 million shs	4.71 million shs
NTLA Intellia Therapeutics	$12.33 -2.8%	$11.95	$7.95 ▼ $28.25	$1.78B	1.82	3.58 million shs	5.03 million shs
NVAX Novavax	$10.55 -2.6%	$8.77	$6.20 ▼ $11.97	$1.79B	2.45	5.47 million shs	5.77 million shs
ZURA Zura Bio	$4.33 -4.0%	$5.51	$2.01 ▼ $7.44	$432.19M	-0.02	1.44 million shs	2.06 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	-9.06%	+21.14%	+10.18%	-4.60%	+274.62%
NTLA Intellia Therapeutics	-2.84%	+7.31%	-1.83%	-23.08%	-27.81%
NVAX Novavax	-2.59%	+12.83%	+19.07%	+23.25%	+21.68%
ZURA Zura Bio	-3.99%	-6.07%	-31.27%	-4.63%	+110.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$9.74 -9.1%	$8.71	$2.24 ▼ $12.06	$1.84B	2.42	3.58 million shs	4.71 million shs
NTLA Intellia Therapeutics	$12.33 -2.8%	$11.95	$7.95 ▼ $28.25	$1.78B	1.82	3.58 million shs	5.03 million shs
NVAX Novavax	$10.55 -2.6%	$8.77	$6.20 ▼ $11.97	$1.79B	2.45	5.47 million shs	5.77 million shs
ZURA Zura Bio	$4.33 -4.0%	$5.51	$2.01 ▼ $7.44	$432.19M	-0.02	1.44 million shs	2.06 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	-9.06%	+21.14%	+10.18%	-4.60%	+274.62%
NTLA Intellia Therapeutics	-2.84%	+7.31%	-1.83%	-23.08%	-27.81%
NVAX Novavax	-2.59%	+12.83%	+19.07%	+23.25%	+21.68%
ZURA Zura Bio	-3.99%	-6.07%	-31.27%	-4.63%	+110.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.80	Moderate Buy	$13.71	40.80% Upside
NTLA Intellia Therapeutics	2.35	Hold	$20.98	70.14% Upside
NVAX Novavax	2.33	Hold	$14.00	32.70% Upside
ZURA Zura Bio	2.86	Moderate Buy	$17.00	292.61% Upside

Current Analyst Ratings Breakdown

Latest ZURA, NVAX, NTLA, and ABSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	ABSI Absci	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
9/9/2026	ABSI Absci	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/9/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$30.00
9/9/2026	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$12.00 ➝ $13.00
9/9/2026	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/8/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$15.00
9/8/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $16.00
8/25/2026	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/25/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$30.00
8/12/2026	ZURA Zura Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$15.00 ➝ $22.00
8/12/2026	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $20.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$2.80M	596.96	N/A	N/A	$1.26 per share	7.73
NTLA Intellia Therapeutics	$67.67M	25.53	N/A	N/A	$5.80 per share	2.13
NVAX Novavax	$1.12B	1.55	$3.41 per share	3.09	($0.79) per share	-13.35
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.80	N/A	N/A	N/A	-7,756.38%	-61.71%	-54.52%	11/16/2026 (Estimated)
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)
NVAX Novavax	$440.30M	-$1.52	N/A	N/A	N/A	-59.87%	-14.82%	-13.35%	11/5/2026 (Estimated)
ZURA Zura Bio	-$99.35M	-$1.13	N/A	N/A	N/A	N/A	-56.13%	-50.15%	11/12/2026 (Estimated)

Latest ZURA, NVAX, NTLA, and ABSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ABSI Absci	-$0.1910	-$0.21	-$0.0190	-$0.21	$0.92 million	$0.32 million
8/11/2026	Q2 2026	ZURA Zura Bio	-$0.1913	-$0.21	-$0.0187	-$0.21	N/A	N/A
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/6/2026	Q2 2026	NVAX Novavax	-$0.3798	-$0.32	+$0.0598	-$0.32	$52.51 million	$56.70 million
6/30/2026	Q2 2026	ZURA Zura Bio	N/A	-$0.21	N/A	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	10.63	10.63
NTLA Intellia Therapeutics	N/A	6.65	6.65
NVAX Novavax	N/A	2.33	2.30
ZURA Zura Bio	N/A	12.90	12.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
NTLA Intellia Therapeutics	88.77%
NVAX Novavax	53.04%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
NTLA Intellia Therapeutics	3.50%
NVAX Novavax	1.60%
ZURA Zura Bio	12.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	140	171.61 million	153.56 million	Optionable
NTLA Intellia Therapeutics	377	140.13 million	135.22 million	Optionable
NVAX Novavax	749	164.95 million	162.31 million	Optionable
ZURA Zura Bio	40	95.83 million	83.98 million	Optionable

ZURA, NVAX, NTLA, and ABSI Headlines

Recent News About These Companies

Zura Bio stock extends multi-month rally on strong pipeline expectations

September 20, 2026 | ad-hoc-news.deA

Zura Bio Limited Class A Ordinary Shares

September 19, 2026 | livemint.com

Zura Bio Limited (ZURA) Latest Press Releases & Corporate News - Yahoo Finance

September 17, 2026 | finance.yahoo.com

Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 16, 2026 | americanbankingnews.com

Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply

September 11, 2026 | finance.yahoo.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Moderate Buy" from Analysts

September 11, 2026 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Shares Down 7.2% - Time to Sell?

September 9, 2026 | marketbeat.com

Montanova Capital LLC Acquires 376,000 Shares of Zura Bio Limited $ZURA

September 1, 2026 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Sees Large Volume Increase - Here's Why

August 25, 2026 | marketbeat.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | businesswire.com

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

August 11, 2026 | businesswire.com

Zura Bio Stock (NASDAQ:ZURAW), Analyst Ratings, Price Targets, Predictions

July 27, 2026 | benzinga.com

William Blair Starts Zura Bio (ZURA) at Outperform

July 14, 2026 | uk.finance.yahoo.com

Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist

July 9, 2026 | businesswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Zura Bio (ZURA)

July 9, 2026 | theglobeandmail.com

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

June 29, 2026 | finance.yahoo.com

Zura Bio (ZURA) Gets a Buy from Oppenheimer

June 13, 2026 | theglobeandmail.com

Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation

June 3, 2026 | finance.yahoo.com

Zura Bio Announces Board Resignation, Governance Stability Affirmed

May 22, 2026 | tipranks.com

Analysts Are Bullish on These Healthcare Stocks: Silence Therapeutics (SLN), Zura Bio (ZURA)

May 11, 2026 | theglobeandmail.com

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

May 7, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA, NVAX, NTLA, and ABSI Company Descriptions

Absci NASDAQ:ABSI

$9.74 -0.97 (-9.06%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$9.62 -0.12 (-1.26%)

As of 06:01 AM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Intellia Therapeutics NASDAQ:NTLA

$12.33 -0.36 (-2.84%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$12.20 -0.13 (-1.01%)

As of 05:55 AM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Novavax NASDAQ:NVAX

$10.55 -0.28 (-2.59%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$10.34 -0.21 (-1.94%)

As of 06:01 AM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Zura Bio NASDAQ:ZURA

$4.33 -0.18 (-3.99%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$4.35 +0.02 (+0.44%)

As of 05:37 AM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZURA, NVAX, NTLA, and ABSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZURA, NVAX, NTLA, and ABSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZURA, NVAX, NTLA, and ABSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA, NVAX, NTLA, and ABSI Company Descriptions

Absci NASDAQ:ABSI

Intellia Therapeutics NASDAQ:NTLA

Novavax NASDAQ:NVAX

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZURA, NVAX, NTLA, and ABSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZURA, NVAX, NTLA, and ABSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZURA, NVAX, NTLA, and ABSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA, NVAX, NTLA, and ABSI Company Descriptions

Absci NASDAQ:ABSI

Intellia Therapeutics NASDAQ:NTLA

Novavax NASDAQ:NVAX

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools